# Corteva, Inc. (CTVA)

> Source: Nexqual · https://nexqual.com/CTVA · data as of 2026-10-22 20:02 UTC · cite as "Nexqual, Corteva, Inc. (CTVA), nexqual.com/CTVA" · informational, not investment advice.

**Price:** USD 12.86 (+1.10% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 12.86 · day 12.52–12.89 · 52w 9.08–14.62 · market cap null · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $17.8B, net income $1.01B (5.7% margin), free cash flow $629M (SEC filings).
- 2 of 80 tracked superinvestors hold CTVA (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Total return with dividends: 1Y +36.3% vs S&P 500 +14.9%; 5Y +111.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD 0.11, revenue estimate $1.76B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $15.7B | $17.5B | $17.2B | $16.9B | $17.4B | $17.8B |
| Gross profit | $6.43B | $7.02B | $7.31B | $7.38B | $8.23B | — |
| Net income | $1.76B | $1.15B | $735M | $907M | $1.09B | $1.01B |
| EPS (diluted) | $0.36 | $0.24 | $0.15 | $0.20 | $0.24 | — |
| Free cash flow | $2.15B | $267M | $1.17B | $1.55B | $2.81B | $629M |
| Gross margin | 41.1% | 40.2% | 42.4% | 43.6% | 47.3% | — |
| Net margin | 11.2% | 6.6% | 4.3% | 5.4% | 6.3% | 5.7% |
| Revenue growth | +10.1% | +11.5% | -1.3% | -1.8% | +2.9% | — |
| Cash + short-term investments | $4.54B | $3.31B | $2.74B | $3.17B | $4.53B | — |
| Total debt | $1.10B | $1.28B | $2.49B | $2.45B | $2.47B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)

P/E at fiscal year-ends: Dec 2025 41.7x, Dec 2024 43.7x, Dec 2023 46.4x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold CTVA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Bill Nygren | Oakmark Funds | 1.84% | $1.38B | Reduced -1.9% |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $1.7M | Reduced -0.7% |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Target lowered | Neutral | $90 → $15 |
| 2026-10-07 | Keybanc | Upgrade | Sector Weight → Overweight | $17 |
| 2026-10-06 | JP Morgan | Upgrade | Neutral → Overweight | $83 → $19 |
| 2026-09-18 | Argus Research | Reiterated | Buy | $91 |
| 2026-09-17 | Citigroup | Target raised | Neutral | $86 → $91 |
| 2026-09-16 | BMO Capital | Target lowered | Outperform | $100 → $95 |
| 2026-09-16 | UBS | Target raised | Neutral | $85 → $90 |
| 2026-09-16 | RBC Capital | Reiterated | Outperform | $103 |
| 2026-09-11 | Keybanc | Initiated | Sector Weight |  |
| 2026-08-18 | UBS | Target lowered | Neutral | $89 → $85 |
| 2026-08-03 | UBS | Target raised | Neutral | $86 → $89 |
| 2026-08-03 | Citigroup | Target raised | Neutral | $85 → $86 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +36.3% | +111.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +36.4% | +16.1% |
| Volatility (annualized) | 30.6% | 27.0% |
| Max drawdown | -16.6% (Jul 2026→Aug 2026) | -34.8% (Nov 2022→Nov 2023) |

## Peers (Agricultural Inputs)
MOS (Mosaic Company (The)) USD 17.27 -2.32% · CF (CF Industries Holdings, Inc.) USD 118.56 +1.94% · SMG (Scotts Miracle-Gro Company (The) USD 59.15 +5.76% · NTR (Nutrien Ltd.) USD 69.09 +1.42% · FMC (FMC Corporation) USD 5.02 -0.20% · IPI (Intrepid Potash, Inc) USD 30.77 -1.38%

## More
Full page: https://nexqual.com/CTVA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name CTVA in their own reports (relationship from CTVA's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Evogene Ltd. (EVGN) | 20-F 2026-03-26 | "Under the terms of the collaboration agreement, AgPlenus and Corteva" |
| partner | Qnity Electronics, Inc. (Q) | 10-K 2026-02-26 | "In connection with their separation, DuPont entered into a letter agreement with Corteva (the "Corteva Letter Agreement") that imposes limitations intended to preserve the agreed allocation of certain…" |
| partner | DuPont de Nemours, Inc. (DD) | 10-K 2026-02-17 | "4.Primarily related to the DWDP Separation and Distribution Agreement and Letter Agreement between Corteva and EIDP and the Electronics Separation and Distribution Agreement with Qnity." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.11 | $0.00 | — | $1.76B | 5 |
| Next quarter (ends 2026-12-31) | $0.27 | $0.00 | — | $2.31B | 4 |
| Current fiscal year (ends 2026-12-31) | $1.11 | $0.00 | — | $7.82B | 7 |
| Next fiscal year (ends 2027-12-31) | $1.13 | $0.00 | — | $8.06B | 8 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-11): ±11.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 48.8% | ±11.1% |
| 2026-12-18 | 56 | 47.5% | ±15.1% |
| 2027-03-19 | 147 | 43.4% | ±21.9% |
| 2027-06-17 | 237 | 60.5% | ±37.7% |